Research programme: cancer therapeutics - Servier/Vernalis/Novartis

Drug Profile

Research programme: cancer therapeutics - Servier/Vernalis/Novartis

Alternative Names: Anti-Mcl-1 inhibitors; Bcl-2 inhibitors; S63845

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Servier; Vernalis
  • Class Small molecules
  • Mechanism of Action Apoptosis regulatory protein inhibitors; MCL1 protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 May 2014 Servier/Vernalis and Novartis agree to co-promote and co-develop apoptosis regulatory protein inhibitor candidates worldwide for Cancer
  • 06 Mar 2013 Vernalis and Servier extend their oncology collaboration
  • 20 Sep 2012 Preclinical development is ongoing in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top